Omega Fund Management, LLC
CIK 0001637359 · BOSTON, MA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$185.7M
2026 Q2
Positions
10
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
100.0%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
BCAX
Bicara Therapeutics Inc.
29.1%
NUVB
Nuvation Bio Inc.
24.7%
KMTS
Kestra Med Technologies Ltd
14.0%
BBOT
BridgeBio Oncology Therapeutics Inc.
13.5%
BBNX
Beta Bionics Inc.
11.1%
ALMS
Alumis Inc.
3.7%
SANA
Sana Biotechnology, Inc.
1.6%
IMA
ImageneBio, Inc.
1.4%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.